Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s | Enterpreneurship
Want create site? Find Free WordPress Themes and plugins.
A Teva Pharmaceutical migraine-prevention drug has won FDA approval, the second therapy in this new drug class to receive the regulatory nod this year.
The Friday approval for the Teva (NYSE: TEVA) drug fremanezumab (Ajovy) came a little earlier than expected; the target date for the FDA decision was Sept. 16. The drug is part of class of drugs called calcitonin gene-related peptides (CGRP). These antibody drugs work by blocking the CGRP protein, which is associated with migraine pain. The Amgen (NASDAQ: AMGN) CGRP drug erenumab (Aimovig) was approved in May.
Amgen’s migraine drug is a once-monthly… Read more »
Reprints | Share: 
UNDERWRITERS AND PARTNERS
Did you find apk for android? You can find new Free Android Games and apps.